BioDelivery Sciences International, Inc. revised earnings guidance for the full year 2021. For the year, the company expected Total Company Net Revenue to be in the range of $165 million to $167 million, compared to previous guidance of $162 million to $167 million.
BioDelivery Sciences International, Inc.
Equities
BDSI
US09060J1060
Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
+32.94% | 709B | |
+30.77% | 595B | |
-1.79% | 367B | |
+20.22% | 334B | |
+5.93% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.02% | 171B |